Fms-like tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutation is related to poor prognosis in normal-karyotype acute myeloid leukemia (AML). However, the prognostic significance of the mutation at relapse has not been adequately investigated. We investigated the prognostic significance of the FLT3 ITD mutation at relapse in normal-karyotype AML patients.
Background
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutation is related to poor prognosis in normal-karyotype acute myeloid leukemia (AML). However, the prognostic significance of the mutation at relapse has not been adequately investigated. We investigated the prognostic significance of the FLT3 ITD mutation at relapse in normal-karyotype AML patients.
Methods
We analyzed 69 normal-karyotype AML patients, in whom paired bone marrow samples taken at initial diagnosis and subsequent relapse were analyzed for the FLT3 ITD mutation at the Asan Medical Center between 1995 and 2009.
Results
Forty patients showed a persistent wild-type genotype, 11 showed the FLT3 ITD mutation at diagnosis and relapse, and 9 lost and another 9 acquired the mutation at relapse. The mutation status at relapse affected the overall survival (OS), with the mutation group showing shorter OS and survival after relapse than the wild-type group did (P＜0.001 and P＜0.001, respectively), despite having received more frequent stem cell transplantation after relapse than the wild-type group did. However, no difference was detected in the OS and survival after relapse with regard to the mutation status at diagnosis.
Conclusion
The patients with FLT3 ITD mutation at relapse showed poorer prognoses than those without the mutation. However, mutation status at diagnosis did not affect the outcome. These results suggest that, in normal-karyotype AML patients with relapse, the prognostic significance of FLT3 ITD mutation at relapse is greater than that of the mutation status at diagnosis.
INTRODUCTION
The Fms-like tyrosine kinase 3 (FLT3) gene encodes a class III receptor tyrosine kinase that plays important roles in cellular proliferation and differentiation [1] [2] [3] [4] [5] [6] [7] [8] . To date, 2 types of FLT3 mutations have been found to induce autophosphorylation through ligand-independent FLT3 dimerization, leading to uncontrolled hematologic progenitor cell proliferation and malignancy. One such mutation is an internal tandem duplication (ITD) of the region between exon 14 and 15 encoding the juxtamembrane domain; the other, in exon 20, is a point mutation in aspartic acid residue 835 (D835) within the activation loop of the second tyrosine kinase domain [9, 10] . The FLT3 ITD mutation is found in approximately 30% of newly diagnosed acute myeloid leukemia (AML) patients, and an association of the mutation with poor prognostic indicators, such as leukocytosis, higher marrow blast counts, shorter overall survival (OS) and event-free survival (EFS), and higher relapse rates, has been firmly established in those with newly diagnosed AML, especially in the intermediate cytogenetic risk group [11] [12] [13] [14] [15] [16] .
The FLT3 D835 mutation occurs less frequently than the FLT3 ITD mutation does, and the prognostic significance of this mutation in newly diagnosed AML patients is less clear, with previous studies reporting conflicting outcomes [17] [18] [19] . In addition to the FLT3 ITD mutation, mutations in the nucleophosmin1 (NPM1) gene are the most frequent genetic alterations, being found in approximately 50% of patients with normal-karyotype AML, and known to be associated with better response to induction therapy and a more favorable outcome in the absence of FLT3 ITD mutations [20] .
Thus far, the prognostic impact of the FLT3 ITD mutation at relapse has not been adequately evaluated in patients with normal-karyotype AML. Therefore, we analyzed FLT3 ITD mutation status at diagnosis and relapse in patients with normal-karyotype AML relapse, and investigated the prognostic significance of FLT3 ITD mutation at relapse.
MATERIALS AND METHODS

Selection of patients and assessment of clinical variables
Paired bone marrow samples collected at diagnosis and relapse from 69 patients newly diagnosed with normal-karyotype AML between 1995 and 2009 at Asan Medical Center were analyzed for FLT3 ITD mutation status. Data for clinical variables, including CBC, blast counts in peripheral blood (PB) and bone marrow (BM), karyotype at initial diagnosis and relapse, and implementation of stem cell transplantation (SCT) were obtained from all patients. The dates of initial diagnosis, first complete remission (CR), first relapse, SCT performance, and death were established by performing a retrospective review of the patients' medical records. CR was defined as the presence of less than 5% blasts with more than 20% cellularity in a standardized BM aspirate after the first or second course of induction chemotherapy. Relapse was defined as more than 5% leukemic blasts in BM aspirates in patients who had previously achieved CR state. OS was defined as the time from diagnosis to death or last follow-up, and survival after relapse was defined as the time from first relapse to death or last follow-up.
Cytogenetic analysis
Cytogenetic analyses were performed on at least 20 metaphases using paired diagnosis and relapse BM samples. According to the classification system proposed by the US Southwest Oncology Group (SWOG), cytogenetic abnormalities at relapse were grouped into 4 categories [21] : (1) . The data is represented as a ratio of mutant cells:wild-type cells. The lowest detection limit of this protocol was 5%, which had been determined by previous serial dilution experiments [22] . For the specimens, in which NPM1 mutation was detected, additional direct sequencing was performed to confirm the mutation subtype.
Analysis of clinical variables related to FLT3 ITD paired mutation status at diagnosis and relapse
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tion status at diagnosis and relapse was performed. Results were grouped into 4 categories: (1) persistent wild type: NN (negative at diagnosis and relapse); (2) acquired mutation: NP (negative at diagnosis and positive at relapse); (3) loss of mutation: PN (positive at diagnosis and negative at relapse); and (4) persistent mutation: PP (positive at diagnosis and relapse). The clinical variables described above were compared individually between NN and PN, NN and NP, NN and PP, and PN and PP groups. Two additional comparisons were made: between patients positive for FLT3 ITD mutation at relapse (NP+PP) and those negative for FLT3 ITD mutation at relapse (NN+PN), and between patients positive for FLT3
ITD mutation at diagnosis (PN+PP) and those negative for FLT3 ITD mutation at diagnosis (NN+NP). Additionally, we compared the prognosis in patients without FLT3 ITD mutation stratifying according to NPM1 mutation status at diagnosis or relapse to identify the prognostic impact of NPM1
mutations. We also compared the prognosis of patients on the basis of FLT3 ITD mutant:wild-type ratio in patients with the mutation at diagnosis or relapse in order to evaluate the effect of the amount of mutation on the prognosis.
Multivariate analysis of OS and survival after relapse with respect to variables, including FLT3 ITD mutation status at diagnosis and relapse
Multivariate analysis of OS and survival after relapse with respect to FLT3 ITD mutation status at diagnosis and relapse was performed. For the analysis at diagnosis, WBC counts and blast percentage in PB and BM, which were found to be significantly different among FLT3 ITD mutation groups in univariate analysis, were used to adjust the relevant outcomes. For the analysis at relapse, duration of CR and SCT performance rates after relapse, which showed significant differences among FLT3 ITD mutation groups in univariate analysis, were used to adjust the dependent measures.
Statistical analysis
Pearson's chi-squared or Fisher's exact tests (for small numbers) were used to compare categorical variables. MannWhitney U test was used to compare continuous variables.
Estimations of OS and survival after relapse were performed using Kaplan-Meier methods and compared using log-rank test. Multivariate analyses of OS and survival after relapse were performed using Cox's proportional hazards model. For all analyses, tests were two-tailed, and P-values≤0.05 were considered statistically significant. All calculations were performed using SPSS 13.0.1 for Windows (SPSS Inc, Chicago, IL, USA).
RESULTS
Overall patient characteristics
All patients achieved first CR after a median interval of 32.0 days and relapsed within a median of 7.6 months from the first CR. A second CR was achieved in 26 patients (37.7%), of whom 8 Abbreviations: FAB, French-American-British classification; CR, complete remission; FLT3 ITD, fms-like tyrosine kinase3 internal tandem duplication; NN, negative at diagnosis and relapse; PN, positive at diagnosis and negative at relapse; NP, negative at diagnosis and positive at relapse; PP, positive at diagnosis and relapse; ns, not significant; Hb, hemoglobin; WBC, white blood cell; PLT, platelet; PB, peripheral blood; BM, bone marrow; SCT, stem cell transplantation; NPM1, nucleophosmin. Abbreviations: CR, complete remission; Hb, hemoglobin; WBC, white blood cell; PLT, platelet; PB, peripheral blood; BM, bone marrow; SCT, stem cell transplantation; FLT3 ITD, fms-like tyrosine kinase3 internal tandem duplication; NN, negative at diagnosis and relapse; PN, positive at diagnosis and negative at relapse; NP, negative at diagnosis and positive at relapse; PP, positive at diagnosis and relapse; ns, not significant. the PN+PP group showed significantly higher blast percentage in PB (68.0% vs. 47.0%; P =0.006) and in BM (87.0% vs. 61.3%, P =0.005) than the NN+NP group did. However, there was no difference in the duration of CR, there was no difference in OS and survival after relapse between these groups (Fig. 1) . Another comparison was performed between the NN+PN group, which included patients with negative FLT3 ITD mutation status at relapse, and the NP+PP group, which included patients with positive FLT3 ITD mutation status at relapse, revealed that the median duration of CR was significantly shorter in the NP+PP group (6.8 months)
than in the NN+PN group (10.0 months; P=0.034). In particular, the median OS was significantly shorter in the NP+PP group (12.0 months) than in the NN+PN group (23.1 months;
P＜0.001), as was survival after relapse (5.5 vs. 11.8 months; P ＜0.001), despite the fact that SCT was performed significantly more frequently in the NP+PP group than in the NN+PN group after the first relapse (66.7% vs. 20.4%; P ＜0.001) (Fig. 2) .
Comparison of prognosis in patients without FLT3 ITD mutation stratified by NPM1 genotype status at diagnosis and relapse
Patients with NPM1 mutation at diagnosis showed a trend (compared with negative at diagnosis) a) P -value was adjusted for WBC count, duration of CR, blast percentage in PB and BM at diagnosis, and SCT performance rates after 1 st relapse, b) P -value was adjusted for WBC count and blast percentage in PB and BM at diagnosis. Abbreviations: HR, hazard ratio; FLT3 ITD, fms-like tyrosine kinase3 internal tandem duplication; ns, not significant; CI, confidence interval. However, these differences were not statistically significant.
Patients with NPM1 mutation at relapse also showed no differences in OS (15.4 vs. 23.1 months; P=0.609) and duration of CR (8.6 vs. 10.3 months; P =0.657) compared with those without NPM1 mutation at relapse.
Comparison of prognosis in patients with FLT3 ITD mutation at diagnosis or relapse according to the amount of FLT3 ITD mutants
The high/low cut-off ratio was set at 0.66, as described in a previous study [23] . Six patients with a high mutant:wild ratio (≥0.66) at diagnosis showed trends towards shorter OS (9.3 vs. 22.5 months; P =0.370) and duration of CR (4.1 vs. 6.6 months; P =0.682) than 14 patients with a low ratio (＜0.66) at diagnosis, suggesting possible poor prognosis, but the results were not statistically significant. Eight patients with high mutant:wild ratios (≥0.66) at relapse also showed similar OS (9.2 vs. 10.1 months; P =0.734) and duration of CR (4.1 vs. 5.4 months; P =0.701) as shown by 12 patients with a low ratio (＜0.66) at relapse.
6. Multivariate analysis of OS and survival after relapse related to FLT3 ITD mutation status at diagnosis and relapse Table 4 shows the results of multivariate analysis of OS and survival after relapse related to FLT3 ITD mutation status at diagnosis and relapse. FLT3 ITD mutation at relapse, irrespective of the initial mutation status, showed a statistically significant association with a poor prognosis on OS (HR, 2.486; P =0.014) and survival after relapse (HR, 2.042; P = 0.039). FLT3 ITD mutation at diagnosis did not show statistically significant prognostic impact on OS or survival after relapse.
DISCUSSION
In this study, the FLT3 ITD mutation was present in 20 (29.0%) patients each at diagnosis and relapse, similar to the findings of a recent study [22] . Between diagnosis and relapse, the FLT3 ITD mutation status changed in 18 patients (26.1%). This figure is quite high relative to the recently reported value of 17.5%, and reflects the heterogeneity of FLT3 ITD mutation populations [24] . Patients with persistent FLT3 ITD mutation showed higher initial WBC counts than those with persistent wild-type Sang Hyuk Park, et al.
status. Patients with loss of the FLT3 ITD mutation at relapse showed higher initial WBC count, blast percentage in PB and BM than those with persistent wild-type status, consistent with the previous findings [11] [12] [13] [14] [15] [16] . Patients who acquired the FLT3 ITD mutation at relapse showed significantly shorter OS and survival after relapse than those with persistent wild-type status, and similar differences were observed between patients who acquired the FLT3 ITD mutation at relapse and patients with persistent FLT3 ITD mutation. Additionally, patients with persistent FLT3 ITD mutation showed a significantly shorter duration of CR than those with persistent wild-type status. These findings were most pronounced in patients with FLT3 ITD mutation at relapse, compared to those with mutation-negative status at relapse, despite SCT being significantly more frequently performed after the first relapse in patients with FLT3 ITD mutation. Collectively, the results suggest that FLT3 ITD mutation at relapse is a poor prognostic indicator, and are consistent with recent data that reported a shorter time-to-relapse in patients with FLT3 ITD mutation at relapse compared to those without the mutation [24] . On the other hand, FLT3
ITD mutation status at diagnosis influenced WBC count and blast percentage in PB and BM at diagnosis, but prognostic differences according to mutation status at diagnosis were not statistically significant. These differences between the prognostic potential of mutation status at diagnosis and relapse may indicate that the prognostic impact of FLT3 ITD mutation status at relapse is more pronounced than the mutation status at diagnosis in normal-karyotype AML patients with relapse.
Multivariate analysis revealed the FLT3 ITD mutation at relapse to be an independent indicator of poor prognosis for both OS and survival after relapse. Otherwise, the presence of FLT3 ITD mutation at diagnosis did not show any prognostic effect. These results support our speculation that the impact of FLT3 ITD mutation status at relapse is of greater prognostic value than the mutation status at diagnosis in normal-karyotype AML patients with relapse. Thus far, FLT3 ITD mutation status at diagnosis has been firmly established as a prognostic indicator for normal-karyotype AML [25, 26] . Moreover, the ratio of mutant:wild-type cells has been suggested to be a possible prognostic indicator by a previous study, which showed significantly lower 5-year relapse-free survival rates (57% vs. 79%, P=0.048) in patients with a high mutant:wild-type ratio (≥0.66) than in those with a low ratio. However, in our study, not only did the FLT3 ITD mutation status at diagnosis not predict outcome but there was also no evidence of a prognostic impact of the relative amount of the mutant cells. One possible explanation for the discordant results is the different nature of the patient group included in the analysis. Previous studies have focused on FLT3 ITD mutation status at initial diagnosis;
therefore, all patients could be included into analysis regardless of their status at relapse. However, in our study, only patients who had undergone a relapse could be enrolled. Because the clinical outcome between relapsed and nonrelapsed patients is quite different, this heterogeneity might influence the clinical outcome. Our study had some limitations. First, several molecular aberrations which have potential prognostic impacts in normal karyotype AML, such as CCAAT-enhancer binding protein-α (CEBPA) and Wilm's tumor 1 (WT1), were not analyzed. These factors may have influenced our results. Second, the number of patients was relatively small, which may lead to false positives or negatives and thus would have affected our conclusions. Third, although we found that a prognostic impact of NPM1 mutation was not evident at either diagnosis or relapse in patients in the absence of FLT3 ITD mutation, this analysis suffered from low statistical power due to the limited number of patients. For this reason, we could not perform more categorized analysis based on the different mutation status combination of FLT3 ITD and NPM1, which has been widely used in recent studies.
Therefore, further studies with larger patient populations will be required for more accurate analysis.
In conclusion, patients with acquired or persistent FLT3 ITD mutation at relapse showed significantly shorter OS and survival after relapse than those with persistent wildtype status. These statistical differences were most pronounced in patients with FLT3 ITD mutation at relapse, when compared to those with mutation-negative status at this time point. However, the mutation status at diagnosis did not affect the outcome. Collectively, these results suggest that the impact of FLT3 ITD mutation status at relapse is expected to be of greater prognostic value than the mutation status at diagnosis in normal karyotype-AML patients with relapse.
